Promoting activity of (α4)(3)(β2)(2) nicotinic cholinergic receptors reduces ethanol consumption

There is increasing interest in developing drugs that act at α4β2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use disorder. The smoking cessation agent varenicline, a partial agonist of α4β2 nAChRs, reduces alcohol intake, but its use can be limited by side effects at high therapeuti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuropsychopharmacology
Main Authors: Wang, Jingyi, Blasio, Angelo, Chapman, Holly L., Doebelin, Christelle, Liaw, Victor, Kuryatov, Alexander, Giovanetti, Simone M., Lindstrom, Jon, Lin, Li, Cameron, Michael D., Kamenecka, Theodore M., Pomrenze, Matthew B., Messing, Robert O.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6901472/
https://ncbi.nlm.nih.gov/pubmed/31394567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41386-019-0475-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados